About BridgeBio
BridgeBio is a publicly listed company based in Palo Alto (United States) founded in 2015 by Neil Kumar and Frank McCormick, and was acquired by Bristol-Myers Squibb in May 2022. Therapeutics for genetic diseases are developed through targeted interventions. BridgeBio has raised $434.2 million across 5 funding rounds from investors including KKR, AIG and Hercules Capital. The company has 730 employees. BridgeBio has completed 1 acquisition, including Eidos Therapeutics. Its chief executive, as recorded, is Neil Kumar. Its website bridgebio.com draws about 33 thousand monthly visits. BridgeBio offers products and services including Attruby and Nulibry. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is BridgeBio Pharma, Inc. Its competitors include Insitro, Moderna and Forge Biologics; 3 of its 3 listed competitors have raised funding.
Company details
The company was founded in 2015 in Palo Alto, United States, and operates in the biotechnology sector focused on genetic diseases. Opportunities for therapeutic intervention are identified by mapping genetic disease landscapes. Drug candidates, such as PTCH1-inhibitors for Gorlin syndrome and S1P-lyase inhibitors for Darier and Hailey-Hailey diseases, are advanced through clinical development. Operations emphasize precision medicine approaches to address unmet needs in rare genetic conditions.
- Headquarters Palo Alto, United States
- Employees 730
- Founders Neil Kumar, Frank McCormick
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website bridgebio.com
- Social LinkedIn X YouTube
- Acquired by Bristol-Myers Squibb (May 2022)
- Legal Name Bridgebio Pharma, Inc.
- Annual Revenue$502.08 M (USD)126.26as on Dec 31, 2025
- Net Profit-$724.93 M (USD)-35.31as on Dec 31, 2025
- EBITDA-$496.63 M (USD)13.07as on Dec 31, 2025
- Total Equity Funding$434.2M (USD)
in 5 rounds
- Latest Funding Round$200M (USD), Post-IPO
Apr 2024
- InvestorsKKR
& 19 more
- Employee Count730
- Investments & Acquisitions
- Acquired byBristol-Myers Squibb
(May 2022)
Products & Services of BridgeBio
BridgeBio offers a comprehensive portfolio of products and services, including Attruby and Nulibry.
Treatment for specific genetic diseases through targeted therapy.
Medicine for genetic conditions affecting patient health.
Apps and channels of BridgeBio
its YouTube channel BridgeBio Pharma has 283 subscribers and 30 videos.
Videos from BridgeBio
The most watched videos on BridgeBio's YouTube channel, BridgeBio Pharma (283 subscribers). Click a video to play it here.
More on BridgeBio Pharma.
Funding Insights of BridgeBio
BridgeBio has successfully raised a total of $434.2M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $200 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $434.2M
- Total Rounds 5
- Last Round Post-IPO — $200M
- First Round $135M
(Sep 2017)
- Investors Count 19
All 5 funding rounds of BridgeBio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2024 | $200M | Post-IPO | – | – | |
| Feb 2021 | $4.5M | Post-IPO | – | – | |
| Jan 2021 | $650M | Post-IPO | – | – | – |
| Jan 2019 | $299.2M | Series D | – | KKR, Viking Global Investors | |
| Sep 2017 | $135M | Series D | – | Viking Global Investors, KKR |
20 investors in total: 20 institutional.
Investors in BridgeBio
BridgeBio has secured backing from 20 investors, including institutional and venture fund investors. Prominent investors backing the company include KKR, AIG and Hercules Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multiple sectors are invested in by this private equity firm. | 1976 | kkr.com | New York, United States | |
Private investment firm focused on multiple sectors | vikingglobal.com | Greenwich, United States | ||
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Venture debt financing is provided to companies in multiple sectors. | 2003 | htgc.com | Palo Alto, United States | |
PE firm investing in the US | aislingcapital.com | New York, United States | ||
Sequoia Capital is engaged in venture capital investments. | 1972 | sequoiacap.com | ||
Venture capital firm | omegafunds.com | Boston, United States | ||
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
Corporate backed venture capital fund investing in multiple sectors | gv.com | Mountain View, United States | ||
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com |
Investor details for BridgeBio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of BridgeBio
220 people are tracked at BridgeBio (155 in leadership, 2 in board & advisors, 63 in team); the tracked headcount is 730.
| Name | Role | Group |
|---|---|---|
Neil Kumar | Co-Founder & CEO | Leadership |
Frank McCormick | Co-Founder | Leadership |
Jeshaune Jackson | Director Strategic Alliances | Leadership |
Liana Duran Hennum | Sr. Director US Value And Health Economics | Leadership |
Eric David | CEO, Gene Therapy | Leadership |
Adora Ndu | Chief Regulatory Affairs Officer | Leadership |
Clayton Beard | Chief Scientific Officer, Gene Therapy | Leadership |
Justin To | COO, Gene Therapy | Leadership |
Chinmay S. | Senior Vice President, Strategic Finance | Leadership |
Andrew Lee | Senior Director, Global Health Economics And Outcomes Research | Leadership |
Jonathan Fox | CMO, Cardiorenal | Leadership |
Shweta Rane | Executive Director | Leadership |
Matthew Hawes | Area Sales Director | Leadership |
Uma Sinha | Chief Scientific Officer | Leadership |
Thomas Gnielinski | VP, Law Commercial & Compliance | Leadership |
Thomas Trimarchi | President And Chief Financial Officer | Leadership |
Michael Guerrero | VP, Technical Development & Operations | Leadership |
Nick Keenan | VP, Information Technology | Leadership |
Julie Hoegi | Vice President | Leadership |
Arun Mathew | Executive Director, Medical Affairs | Leadership |
200 more people are available in the full profile.
Complete people profiles for BridgeBio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of BridgeBio
BridgeBio is a publicly listed company on the NASDAQ with ticker symbol BBIO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date05 Jul 2019
- Listed onFRA: 2CL
- Listed entityBridgeBio Pharma, Inc.
- Exchange sectorHealth technology
- ISINUS10806X1028
- Share price$63.30 (-3.73% on the day) · 2026-10-13
- Market capitalisation$12.37B
- EPS (diluted, trailing year)$-3.57
- Volume (last session)2,709,167
Financials of BridgeBio
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $502.1M | -$724.9M | -$496.6M |
| 2024 | $221.9M | -$535.8M | -$571.3M |
| 2023 | $9.3M | -$643.2M | -$593.0M |
| 2022 | $77.7M | -$481.2M | -$461.7M |
| 2021 | $69.7M | -$562.5M | -$570.8M |
Detailed financial statements for BridgeBio
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by BridgeBio
BridgeBio has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Eidos Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Small-molecule treatments for transthyretin amyloidosis are developed. | eidostx.com | Palo Alto, United States | 2016 | Oct 2020 | •••• |
Complete acquisition details for BridgeBio
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of BridgeBio
6 dated milestones of BridgeBio across 9 years, from founding to its latest funding, stage changes and deals.
- Founded BridgeBio is founded.
- Funding First funding round of $135.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Eidos Therapeutics.
- Exit Acquired by Bristol-Myers Squibb.
- Funding Latest funding round, Post-IPO, of $200.0M.
Competitors of BridgeBio
BridgeBio has 3 listed competitors in our database, 3 of them funded. They include Insitro, Moderna and Forge Biologics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. |
Detailed competitors of BridgeBio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of BridgeBio
The website of BridgeBio (bridgebio.com) receives about 33K visits a month.
- Monthly visits33K
▲ 68.1% vs previous month
Websites whose visitors overlap most with BridgeBio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| astellasgenetherapies.com | 100% | 1K | View details | ||
| corvuspharma.com | 98% | 13.6K | #3,366,661 | View details | |
| mbcbiolabs.com | 97% | #2,013,343 | View details | ||
| eurekatherapeutics.com | 96% | 1.7K | #7,320,910 | View details | |
| nurixtx.com | 95% | 11.5K | #2,207,206 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for BridgeBio
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as BridgeBio (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bridgebio
Complete news archive for BridgeBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BridgeBio
BridgeBio was founded in 2015 and raised its 1st funding round 2 years after it was founded.
BridgeBio is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Neil Kumar is the CEO of BridgeBio, as recorded in our data. They have also founded this company.
BridgeBio is a funded company, having raised a total of $434.2M across 5 funding rounds to date. The company's 1st funding round was a Series D of $135M, raised on Sep 2017.
BridgeBio has 730 employees.
Annual revenue of BridgeBio is $502.08M as on Dec 31, 2025.
The company was founded in 2015 in Palo Alto, United States, and operates in the biotechnology sector focused on genetic diseases. Opportunities for therapeutic intervention are identified by mapping genetic disease landscapes. Drug candidates, such as PTCH1-inhibitors for Gorlin syndrome and S1P-lyase inhibitors for Darier and Hailey-Hailey diseases, are advanced through clinical development. Operations emphasize precision medicine approaches to address unmet needs in rare genetic conditions.
BridgeBio's top competitors include Moderna, Forge Biologics and Insitro.
BridgeBio offers Attruby and Nulibry.
Yes, BridgeBio is publicly traded on NASDAQ under the ticker symbol BBIO.
BridgeBio has made 1 acquisition, including Eidos Therapeutics.
BridgeBio has 20 investors. Key investors include KKR, AIG, Hercules Capital, Citadel, and Bristol-Myers Squibb.